S'abonner

Loop Diuretics in Severe Bronchopulmonary Dysplasia: Cumulative Use and Associations with Mortality and Age at Discharge - 22/03/21

Doi : 10.1016/j.jpeds.2020.10.073 
Nicolas A. Bamat, MD, MSCE 1, , Timothy D. Nelin, MD 2, Eric C. Eichenwald, MD 3, Haresh Kirpalani, BM, MSc 3, Matthew M. Laughon, MD, MPH 4, Wesley M. Jackson, MD, MPH 4, Erik A. Jensen, MD, MSCE 3, Kathleen A. Gibbs, MD 3, Scott A. Lorch, MD, MSCE 3
1 Division of Neonatology and Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA 
2 Pediatrics Residency Program, Children's Hospital of Philadelphia, Philadelphia, PA 
3 Division of Neonatology, Children's Hospital of Philadelphia, Philadelphia, PA 
4 Division of Neonatology, Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC 

Reprint requests: Nicolas A. Bamat, MD, MSCE, Division of Neonatology, Children's Hospital of Philadelphia, Roberts Center for Pediatric Research, 2716 South Street, Room 19360, Philadelphia, PA 19146Division of NeonatologyChildren's Hospital of PhiladelphiaRoberts Center for Pediatric Research2716 South StreetRoom 19360PhiladelphiaPA19146

Abstract

Objectives

To measure between-center variation in loop diuretic use in infants developing severe bronchopulmonary dysplasia (BPD) in US children's hospitals, and to compare mortality and age at discharge between infants from low-use centers and infants from high-use centers.

Study design

We performed a retrospective cohort study of preterm infants at <32 weeks of gestational age with severe BPD. The primary outcome was cumulative loop diuretic use, defined as the proportion of days with exposure between admission and discharge. Infant characteristics associated with loop diuretic use at P < .10 were included in multivariable models to adjust for center differences in case mix. Hospitals were ranked from lowest to highest in adjusted use and dichotomized into low-use centers and high-use centers. We then compared mortality and postmenstrual age at discharge between the groups through multivariable analyses.

Results

We identified 3252 subjects from 43 centers. Significant variation between centers remained despite adjustment for infant characteristics, with use present in an adjusted mean range of 7.3% to 49.4% of days (P < .0001). Mortality did not differ significantly between the 2 groups (aOR, 0.98; 95% CI, 0.62-1.53; P = .92), nor did postmenstrual age at discharge (marginal mean, 47.3 weeks [95% CI, 46.8-47.9 weeks] in the low-use group vs 47.4 weeks [95% CI, 46.9-47.9 weeks] in the high-use group; P = .96).

Conclusions

A marked variation in loop diuretic use for infants developing severe BPD exists among US children's hospitals, without an observed difference in mortality or age at discharge. More research is needed to provide evidence-based guidance for this common exposure.

Le texte complet de cet article est disponible en PDF.

Keywords : premature infant, bronchopulmonary dysplasia, artificial respiration, diuretics, medication therapy management

Abbreviations : BPD, NICU, PHIS, PMA


Plan


 Supported by a National Institutes of Health Institutional National Research Service Award (2T32HD060550-06, to N.B.) and National Heart, Lung and Blood Institute (K24 HL143283, to M.L.). The funding sources had no role in the study design; collection, analysis, and interpretation of the data; writing of the report; or decision to submit the manuscript for publication. The authors declare no conflicts of interest.


© 2020  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 231

P. 43 - avril 2021 Retour au numéro
Article précédent Article précédent
  • A Substantial Proportion of 6- to 12-Month-Old Infants Have Calculated Daily Absorbed Iron below Recommendations, Especially Those Who Are Breastfed
  • Steven A. Abrams, Joel C. Hampton, Kristen L. Finn
| Article suivant Article suivant
  • 50 Years Ago in The Journal of Pediatrics : Exocrine Pancreas Insufficiency: Supplementing Our Way to Success
  • Kevin M. Murray, Stephanie B. Oliveira

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.